PRTC PureTech Health plc

1.528USD116.00 GBp · LSE-1.19%Mkt Cap: 371.83M USDP/E: —

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential…

Institutional holders11 on file

Key Statistics

Company
Market Cap371.83M USD
Enterprise Value355.86M USD
Revenue (TTM)6.37M USD
Gross Profit-59.06M USD
Net Income (TTM)-109.74M USD
Revenue/Share0.03 USD
Last Price1.528 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees90
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BY2Z0H74
Valuation
P/E (Trailing)—
P/E (Forward)-4.78
PEG—
EV/EBITDA-2.67
EV/Revenue55.91
P/S44.36
P/B0.98
EPS (TTM)0.00 USD
EPS (Forward)-0.24 USD
52W Range
1.40425% of range1.891
52W High1.891 USD
52W Low1.404 USD
Profitability
Gross Margin0.00%
Oper. Margin-1614.82%
EBITDA Margin0.00%
Profit Margin-2355.42%
ROE-35.16%
ROA-20.52%
ROIC-203.86%
ROCE-20.17%
Growth
Revenue Growth92.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-85.13M USD
CapEx (TTM)6.00K USD
FCF Margin-1481.68%
FCF Yield-25.36%
Net Debt-8.79M USD
Net Debt/EBITDA0.09
Net Debt/FCF—
Balance Sheet
Debt/Equity0.06
Current Ratio4.60
Quick Ratio4.38
Book Value/Sh1.18 USD
Cash/Share0.95 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)3.990 USD
Upside (mean)+161.2%
Target Range2.535 USD – 6.776 USD
2.535+161.2% to mean6.776
# Analysts5
Ownership
Shares Out.243.42M
Float162.44M
Insiders13.15%
Institutions57.13%
Technical
SMA 501.537 (-0.6%)
SMA 2001.616 (-5.5%)
Beta0.75
S&P 52W Chg12.08%
Avg Vol (30d)448.40K
Avg Vol (10d)489.36K
Technical Indicators
RSI (14)45.0
MACD0.6975
MACD Signal1.3701
MACD Hist.-0.6725
BB Upper1.670 USD
BB Middle1.571 USD
BB Lower1.471 USD
BB Width12.72%
ATR (14)0.0634 USD
Vol Ratio (20d)1.36x

About PureTech Health (LON: PRTC)

›

PureTech Health (LON: PRTC) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 90 employees.

The shares were at 116.00 GBp on 19 November 2026, down 2.5% over 52 weeks. Its 52-week range is 106.60 GBp to 143.60 GBp: the price is 19.2% below the high and 8.8% above the low.

Its market capitalisation is 282.37M GBP.

PureTech Health reports return on equity of -35.2% and revenue up 92.2% year over year.

It holds more cash than debt, a net cash position of 8.79M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock; their mean price target of 303.00 GBp is 161.2% above the current price. The next earnings report is expected on 29 April 2027.